Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
Rapid Dose Therapeutics. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
Rapid Dose Therapeutics's
is considered below, and whether this is a fair price.
Price based on past earnings
Rapid Dose Therapeutics's earnings available for a low price, and how does
this compare to other companies in the same industry?
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Rapid Dose Therapeutics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.
Show me the analysis anyway
The future performance of a company is measured in the same way as past
performance, by looking at estimated
and how much profit it is expected to make.
Future estimates come from
professional analysts. Just like forecasting the weather, they don’t always get
Expected Life Sciences industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Rapid Dose Therapeutics
expected to grow at an
Unable to compare Rapid Dose Therapeutics's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
Unable to compare Rapid Dose Therapeutics's earnings growth to the Canada market average as no estimate data is available.
Unable to compare Rapid Dose Therapeutics's revenue growth to the Canada market average as no estimate data is available.
Unable to determine if Rapid Dose Therapeutics is high growth as no earnings estimate data is available.
Unable to determine if Rapid Dose Therapeutics is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
Rapid Dose Therapeutics's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
Rapid Dose Therapeutics
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
A company's financial position is much like your own financial position,
it includes everything you own
The boxes below represent the relative size of what makes up
Rapid Dose Therapeutics's finances.
The net worth of a company is the difference between its assets and liabilities.
Rapid Dose Therapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
Rapid Dose Therapeutics has no long term commitments.
This treemap shows a more detailed breakdown of
Rapid Dose Therapeutics's finances. If any of them are yellow this
indicates they may be out of proportion and red means they relate to one of the
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
High level of physical assets or inventory.
Rapid Dose Therapeutics has no debt, it does not need to be covered by short term assets.
Nearly all companies have debt. Debt in itself isn’t
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.
The graphic below shows equity (available funds) and debt, we ideally want to
see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and
whether the level has increased over the past 5 years.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
Mr. Mark Andrew Upsdell is the Chief Executive Officer and Director of Rapid Dose Therapeutics Corp. and also serves as President. Mr. Upsdell leads RDT – Rapid Dose Therapeutics, with a unique combination of global business and technology transformational growth experience. His ability to build high-performance growth oriented teams, including his strategically-selected executive management staff, has served as a growth catalyst to drive revenue results. He believes in innovation, strategy and people. He was Senior Global Manager of Strategy and Planning at Cisco, and held director positions within Cisco and Hewlett Packard.
Insufficient data for Mark to compare compensation growth.
Mark's remuneration is lower than average for companies of similar size in Canada.
Senior VP of Business Development & Director
Chief Financial Officer
Marketing & Communications Director
Assistant Corporate Secretary
Board of Directors
Senior VP of Business Development & Director
Who owns this company?
Recent Insider Trading
No 3 month open market individual insider trading information.
Do Directors Own Rapid Dose Therapeutics Corp. (CNSX:DOSE) Shares?
As Nassim Nicholas Taleb said, 'Don’t tell me what you think, tell me what you have in your portfolio.' Rapid Dose Therapeutics is not a large company by global standards. … Check out our latest analysis for Rapid Dose Therapeutics CNSX:DOSE Ownership Summary, May 9th 2019 What Does The Lack Of Institutional Ownership Tell Us About Rapid Dose Therapeutics? … Insider Ownership Of Rapid Dose Therapeutics The definition of an insider can differ slightly between different countries, but members of the board of directors always count.
Rapid Dose Therapeutics Corp., a life sciences company, provides drug delivery technologies designed to improve patient outcomes in Canada. The company’s over the counter products include QuickStrip, a processed oral film that contains the active molecule embedded in the delivery matrix; QuickStrip energy; vitamin B12; and QuickStrip sleep that delivers melatonin to your system. It also PharmaStrip delivery system. The company serves pharmaceutical and healthcare manufacturing industry. Rapid Dose Therapeutics Corp. is based in Burlington, Canada.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.